The purpose was to investigate pharmacokinetic variability of valproic acid (VPA) in women of childbearing age by therapeutic drug monitoring (TDM) data to elucidate the variable relationship between dose and serum concentrations with the ultimate aim of facilitating safer use of VPA. Anonymized retrospective data from the TDM database (2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015) at the National Center for Epilepsy in Norway were used. Trough total concentrations of VPA at assumed steady state in women aged 14-46 years were analyzed. Data from 643 nonpregnant women of childbearing age (mean age = 27 years) were included. Mean dose and serum concentration of VPA were 968 (standard deviation [SD] = 453) mg/day and 411 (SD = 138) lmol/L, respectively, and 59% used polytherapy. The pharmacokinetic variability in serum concentration/dose (C/D) ratios between women was extensive. For doses <700 mg/day (n = 202; 32%; 150-625 mg/day), mean serum concentration was 336 lmol/L and variability in C/D ratio was 10-fold. The variability decreased with increasing dose to eightfold (≥700 to <1,500 mg/day, n = 358) and fourfold (≥1,500 mg/day, n = 96). This study demonstrates the extensive pharmacokinetic variability of VPA among women of childbearing age, which is most pronounced at low doses. In future studies, serum concentrations of VPA, rather than dosage, should be used as a guide for exposure of VPA and possible risks of teratogenicity to evaluate safety aspects of VPA in women.
Valproate (VPA) is recommended not to be used in women of childbearing age because of the risk of teratogenicity, 1,2 but for some women with generalized epilepsies, VPA may be the only effective medication. In this situation, one needs to consider maternal as well as fetal safety. 3, 4 The risk of major congenital malformations (MCMs) [5] [6] [7] as well as adverse effects on the exposed child's cognitive development has been shown to be dependent on the dose of VPA taken by the pregnant woman. 8, 9 When VPA is considered necessary, physicians are therefore advised to use the lowest effective dose, and to strive for doses < 600 mg/day whenever possible. However, cutoffs for increased risks vary between studies, ranging from 500 to 700 mg/day for MCMs and 800 to 1,000 mg/day for poor cognitive development. [5] [6] [7] [8] [9] Studies have used different criteria for exposure, but the maternal dose is also a very crude estimate of fetal drug exposure, not least because of pharmacokinetic variability. The purpose of this study was to investigate pharmacokinetic variability of VPA in women of childbearing age by use of therapeutic drug monitoring (TDM) data to elucidate the variable relationship between dose and serum concentrations with the ultimate aim of facilitating safer use of VPA in women who cannot be treated effectively with other antiepileptic drugs (AEDs).
Methods

Study material
Anonymized retrospective data from a TDM database (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) were used, covering patients admitted to the National Center for Epilepsy, as well as outpatient samples from all parts of Norway. Included samples were trough total concentrations at assumed steady state and taken drugfasting in the morning as a standard procedure, from nonpregnant women 14-46 years of age, where information on dosage of VPA was available. The latest measurement was used for each woman. Drug analyses were routine measurements of validated methods by immunoassay (COBAS C111, Roche Diagnostics, Switzerland; interval for measurements = 20-1,040 lmol/L). The reference range of VPA is 300-700 lmol/L. 10 The study was approved by the regional ethics committee.
Calculations
Serum concentrations, doses, and concentration/dose (C/D) ratios are presented as mean values, and standard deviation (SD) and range were used to express variability. The C/D ratio is the inverse expression of clearance, based on the following equation: CL/F (mL/kg/min) = daily dose (mg/kg)/C ss (mg/L 9 1,000) 9 1,440, where oral clearance is CL/F, CL = clearance, F = oral bioavailability, C ss = serum concentration at steady state, and 1,440 = min/24 h.
Differences in C/D ratios in patients using monotherapy/ drugs considered to be interaction neutral were compared to those patients who used enzyme inducers (carbamazepine, phenobarbital, phenytoin). Oxcarbazepine and eslicarbazepine were studied in a separate group to investigate possible inducing or inhibiting properties on VPA metabolism. The following AEDs were considered interaction neutral for the purpose of this study: clobazam, clonazepam, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, pregabalin, rufinamide, topiramate, and zonisamide. 11 For statistical analyses IBM SPSS Statistics version 22 (SPSS Inc, Chicago, IL, U.S.A.) was used. Univariate analysis was used for linear regression. Student two-sided t-test with unequal variance was used to calculate significant pairwise differences between groups. The nonparametric test one-way analysis of variance was used for multiple comparisons. A probability value of <0.05 was considered statistically significant.
Results
Patient characteristics
Of the 798 women in the relevant age group that had serum concentrations of VPA measured during 2006-2015, 643 were included in the study (details in Table 1 ).
There were 269 women (42%) who used VPA in monotherapy, whereas 387 (58%) used VPA in polytherapy ( Table 1 ). The doses varied from 250 to 3,900 mg/day (mean = 968 mg), and mean serum concentration was 411 lmol/L (range = 21-798). A reason for the TDM request was only noted in 43% of the patients (n = 275). Weight was only noted in 27% (n = 175), and the mean dose was calculated to be 15.5 mg/kg (SD = 7) for those patients. The most commonly used other AEDs were lamotrigine (n = 199), levetiracetam (n = 86), topiramate (n = 48), clobazam (n = 42), and oxcarbazepine (n = 31).
Pharmacokinetic variability
The variability in dose and serum concentration relationship is shown in Fig. 1 . There was a linear correlation (R 2 = 0.22), with a wide range of measured concentrations (21-798 lmol/L). In total, seven women had concentrations < 100 lmol/L, despite doses of 450-1,500 mg/day and no concomitant use of enzyme inducers, possibly due to poor adherence, and were therefore excluded from calculations. The variability in C/D ratios was 14-fold across the total range of doses and serum concentrations (range in C/D ratios = 0.11-1.52). The most commonly used daily dose was 900 mg (n = 140, 22%). Only nine women had serum concentrations > 700 lmol/L. There were 204 women who used doses < 700 mg/day (32%; range = 150-625 mg/day) with a mean serum concentration of 336 lmol/L (range = 21-681 lmol/L), compared to 490 lmol/L in the women on higher doses, and 67% of these women also used concomitant AEDs.
Concomitant use of carbamazepine significantly decreased the C/D ratio of VPA of 21%; no other significant differences with other comedications were noted (but sample sizes of phenobarbital and phenytoin were small; Table 1 ). Variability within the three dose-level categories defined by the EURAP registry showed a significant decrease in variability in C/D ratio with increase in dose ( Table 1 ). The variability was 13-fold in those women using VPA in monotherapy (n = 269; range in C/D ratios = 0.12-1.60).
Discussion
The present study of the use of VPA in a large group of women illustrates that the pharmacokinetic variability is extensive in mono-and polytherapy, and that the dose is a There was an extensive variability in serum concentrations and dose relationships between patients, which cannot be explained by factors such as age or comedication. 12, 13 The degree of variability in C/D ratios differed between low-medium and high VPA dose ranges. A possible explanation could be the saturation of protein binding of VPA with increasing doses and consequently, a shift in distribution from blood at higher concentrations. Total concentration measurements are misleading in such cases, as the free concentration gives a more precise measure of possible fetal exposure. 13 There was a significant decrease in the C/D ratio of VPA in combination with carbamazepine, pointing to increased clearance in line with previous findings (for review, see Johannessen and Landmark 11 ). Other AEDs were used in a limited number of patients, and other drug-drug interactions could not be assessed. Use of extended release formulations could contribute to variability. Drug formulation was not noted on the request form, but the large majority of the use of VPA in Norway includes depot or enteroformulations, based on the Norwegian Prescription Database (2004-2012; Johannessen Landmark, unpublished) .
Keeping the VPA dose as low as possible by use of polytherapy might be an approach to maintain adequate seizure control while minimizing the risk of congenital malformations. 5, 6 Among the women on VPA, 32% used low doses (<700 mg/day), and two-thirds of them used AED polytherapy, which might reflect this strategy.
Previous attempts from pregnancy registries to define teratogenic risks by different levels of exposure to VPA have all been based on dosage and disregarded the pharmacokinetic variability. [5] [6] [7] [8] [9] Our study clearly shows that this is a very crude approximation of potential fetal drug exposure. It is particularly concerning that the variability appears most pronounced at the dose levels that have been reported to be associated with the lowest rates of malformations, because fetal VPA exposure may still be high among outliers using low doses. Fetal drug exposure will also depend on pharmacokinetic changes during pregnancy. 12, 14 This has not been assessed in the present study, but extensive variability was recently demonstrated in 58 women where maternal and umbilical cord concentrations of VPA were measured, where neonatal length and weight were inversely correlated to exposure, that is, to concentration, but not to the dosage. 15 This important finding was made in the only study so far where TDM has been used during pregnancy to study exposure of VPA and outcome in the offspring.
In a retrospective and natural, setting there are limitations that are difficult to control for. Nonetheless, TDM databases are suitable to identify individual and grouprelated differences in pharmacokinetic properties. We did not have any information on other contributing factors such as use of other interacting drug classes (e.g., oral contraceptives that may decrease VPA concentrations by 23% 16 ), nor additional clinical data. For quality assurance of the use of TDM data, we recently compared TDM data based on request forms and data from medical records regarding correct dose, steady-state conditions, and comedication and demonstrated corresponding results. 17 There might be a selection bias in those women in whom serum concentrations were performed, regarding variability or unsatisfactory seizure control. Adherence was controlled for in hospitalized patients by fixed times of drug intake, but the data from outpatients were based on the dose and time of the last drug intake written on the request form.
Conclusions
The present study demonstrated extensive pharmacokinetic variability among women of childbearing age who used VPA. The women who used the low dose of VPA (≤700 mg/day) had a 10-fold variability in C/D ratios, and two-thirds of them used VPA in polytherapy. This variability decreased with increasing doses. This calls for measurement of both total and free serum concentrations of VPA in future studies of teratogenic effects to develop refined strategies for a safer treatment of those women who need VPA to control their epilepsy, rather than just relying on the dose. 
